[
  {
    "ts": null,
    "headline": "Health Care Stocks Climb on Rate Cute Hopes -- Health Care Roundup",
    "summary": "Health Care Stocks Climb on Rate Cute Hopes -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=6d36b273c0241e46a0b057539b2e0de0c0ee2a157ec4dceef90de40e22192955",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754328780,
      "headline": "Health Care Stocks Climb on Rate Cute Hopes -- Health Care Roundup",
      "id": 136208642,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Health Care Stocks Climb on Rate Cute Hopes -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=6d36b273c0241e46a0b057539b2e0de0c0ee2a157ec4dceef90de40e22192955"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Collaborates On Virtual Tumor Models To Advance Cancer Research",
    "summary": "Merck (MRK) recently engaged in a research collaboration with Turbine, focusing on simulations for challenging cancer patient populations, which showcases its commitment to innovation in oncology. Over the last quarter, Merck's stock was flat, a reflection of both broader market trends and company-specific events such as its earnings release that reported declines in sales and net income. The market itself faced volatility, influenced by economic and trade concerns; within this context,...",
    "url": "https://finnhub.io/api/news?id=5e62fefe6a83f53bca8ac4e6cbe8bf3ab013864390667e053ce3ac1296ad2c10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754327671,
      "headline": "Merck (MRK) Collaborates On Virtual Tumor Models To Advance Cancer Research",
      "id": 136200343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently engaged in a research collaboration with Turbine, focusing on simulations for challenging cancer patient populations, which showcases its commitment to innovation in oncology. Over the last quarter, Merck's stock was flat, a reflection of both broader market trends and company-specific events such as its earnings release that reported declines in sales and net income. The market itself faced volatility, influenced by economic and trade concerns; within this context,...",
      "url": "https://finnhub.io/api/news?id=5e62fefe6a83f53bca8ac4e6cbe8bf3ab013864390667e053ce3ac1296ad2c10"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?",
    "summary": "RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.",
    "url": "https://finnhub.io/api/news?id=37dba5c59b51f6138ef916eaed3be2eea296fce2d72a89ab3427d648d7bf14e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754324580,
      "headline": "Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?",
      "id": 136201074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.",
      "url": "https://finnhub.io/api/news?id=37dba5c59b51f6138ef916eaed3be2eea296fce2d72a89ab3427d648d7bf14e0"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754322480,
      "headline": "Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136200228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=883190f0e2f70a7ee2c2c89d4029b1a0d3a68266fb7467a0b0963edd4dee601a"
    }
  },
  {
    "ts": null,
    "headline": "Marex Group plc (MRK) to Acquire Winterflood Securities",
    "summary": "Marex Group plc (NASDAQ:MRX) is one of the Best Undervalued UK Stocks to Buy According to Analysts. On July 25, Marex Group plc (NASDAQ:MRX) announced that it has agreed to acquire Winterflood Securities from Close Brothers for £103.9 million in cash. Winterflood is a major UK equity market maker, serving more than 400 institutional clients and […]",
    "url": "https://finnhub.io/api/news?id=2759c9b91351070741784540455ae7c8fb35eb08be3681587e05856c6c7fc264",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754316149,
      "headline": "Marex Group plc (MRK) to Acquire Winterflood Securities",
      "id": 136200346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Marex Group plc (NASDAQ:MRX) is one of the Best Undervalued UK Stocks to Buy According to Analysts. On July 25, Marex Group plc (NASDAQ:MRX) announced that it has agreed to acquire Winterflood Securities from Close Brothers for £103.9 million in cash. Winterflood is a major UK equity market maker, serving more than 400 institutional clients and […]",
      "url": "https://finnhub.io/api/news?id=2759c9b91351070741784540455ae7c8fb35eb08be3681587e05856c6c7fc264"
    }
  },
  {
    "ts": null,
    "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
    "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
    "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754310600,
      "headline": "Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas",
      "id": 136197991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trum",
      "url": "https://finnhub.io/api/news?id=871bf0ffcbc0ded573fd4e67ce5cf9a0b951f3012c64f0c0f43e2dadd96a7a2c"
    }
  },
  {
    "ts": null,
    "headline": "GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?",
    "summary": "GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=a8d08a4c8620f43c48e394a30891ae9fdd8fec8a4c753e819419b018da8dd29b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754308680,
      "headline": "GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?",
      "id": 136197992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=a8d08a4c8620f43c48e394a30891ae9fdd8fec8a4c753e819419b018da8dd29b"
    }
  },
  {
    "ts": null,
    "headline": "Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement",
    "summary": "WAYNE, Pa. & NEW YORK, August 04, 2025--Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta.",
    "url": "https://finnhub.io/api/news?id=9b15d5a944d25a5748d7dc08ea573680198b00a8e293d1b03cd6172b6781b55a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754307000,
      "headline": "Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement",
      "id": 136197862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "WAYNE, Pa. & NEW YORK, August 04, 2025--Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta.",
      "url": "https://finnhub.io/api/news?id=9b15d5a944d25a5748d7dc08ea573680198b00a8e293d1b03cd6172b6781b55a"
    }
  },
  {
    "ts": null,
    "headline": "Is Wall Street Bullish or Bearish on Merck Stock?",
    "summary": "Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.",
    "url": "https://finnhub.io/api/news?id=6ffb580d68d22a6027b332bb5f09b416a1ceb0b4795b2b514f77fa81b1941e63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754305604,
      "headline": "Is Wall Street Bullish or Bearish on Merck Stock?",
      "id": 136197994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Despite Merck’s underperformance relative to the broader market over the past year, analysts continue to maintain fair confidence regarding its future potential.",
      "url": "https://finnhub.io/api/news?id=6ffb580d68d22a6027b332bb5f09b416a1ceb0b4795b2b514f77fa81b1941e63"
    }
  },
  {
    "ts": null,
    "headline": "Turbine to Simulate Hard-to-Treat Cancer Populations with AI for Identification of Novel Dependencies through Collaboration with MSD",
    "summary": "Turbine, a leading developer of cell simulations with AI, today announced a research collaboration with MSD (the tradename of Merck & Co., Inc., Rahway NJ USA) to create simulations of cancer patient populations that remain difficult to treat and study in laboratory settings.",
    "url": "https://finnhub.io/api/news?id=9d7d41d0f56a71f614bb2943a2f388d22560ba0f144583e69caad4c6ba921c85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754301600,
      "headline": "Turbine to Simulate Hard-to-Treat Cancer Populations with AI for Identification of Novel Dependencies through Collaboration with MSD",
      "id": 136197995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Turbine, a leading developer of cell simulations with AI, today announced a research collaboration with MSD (the tradename of Merck & Co., Inc., Rahway NJ USA) to create simulations of cancer patient populations that remain difficult to treat and study in laboratory settings.",
      "url": "https://finnhub.io/api/news?id=9d7d41d0f56a71f614bb2943a2f388d22560ba0f144583e69caad4c6ba921c85"
    }
  }
]